Cohance Lifesciences Limited
COHANCE
Rang in aandelen
#6337
Headquartered in Hyderabad, Cohance Lifesciences Limited operates as a... Headquartered in Hyderabad, Cohance Lifesciences Limited operates as a pharmaceutical enterprise, with primary expertise in contract development and manufacturing (CDMO) services. Its business scope also includes the creation of active pharmaceutical ingredients (APIs) and diverse specialty chemicals. The company, previously known as Suven Pharmaceuticals Limited, underwent a corporate rebranding following its amalgamation with Cohance Lifesciences, a transition officially effective May 1, 2025.
Aandeelprijs
$5.09
Marktkapitalisatie
$1.95B
Verandering (1 dag)
0.79%
Verandering (1 jaar)
-57.04%
Land
IN
Handel Cohance Lifesciences Limited (COHANCE)
Categorie
Healthcare
P/B-ratio voor Cohance Lifesciences Limited (COHANCE)
P/B-ratio op October 2026 TTM: 22.54
Volgens de meest recente financiële rapporten en aandelenkoers van Cohance Lifesciences Limited is de huidige P/B-ratio (TTM) 22.54. Eind 2024 had het bedrijf een P/B-ratio van 8.31.
P/B-ratiohistoriek voor Cohance Lifesciences Limited van 2019 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 22.54 | 41.50% |
| 2025 | 15.93 | 91.72% |
| 2024 | 8.31 | 19.91% |
| 2023 | 6.93 | -32.77% |
| 2022 | 10.31 | -3.75% |
| 2021 | 10.71 | 253.56% |
| 2020 | 3.03 | -58.32% |
| 2019 | 7.27 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | -77.64% |
IN
|
